SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (151)10/29/1997 11:19:00 PM
From: John McCarthy  Respond to of 1510
 
MJ -

One of my concerns is that IMNR will be out of
cash by June.

Their sucking it at the rate of $28 mil. a yr.

A lukewarm 'anything' about Remune is going to
make next yr's new capital structure a bit
tough for current shareholders.

OTOH, a more favorable outlook on Remune - for any
reason - will make things a bit more comfortable.

Note: I've E-mailed the company and addressed it to
the REMUNE group. We'll see.

Regards,

John McCarthy


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News